Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an update.
Kontafarma China Holdings Ltd has announced a restructuring of its board of directors, effective November 14, 2025. The company has appointed Wang Feifei as Chairman and President, with Guo Zixiu as Financial Controller, and Liu Jiankun as an Executive Director. The board also includes a Non-Executive Director and three Independent Non-Executive Directors. This restructuring is likely to impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder confidence.
More about Kontafarma China Holdings Ltd
Average Trading Volume: 5,734,550
Technical Sentiment Signal: Sell
Current Market Cap: HK$150.6M
For an in-depth examination of 1312 stock, go to TipRanks’ Overview page.

